Reumatizam, Vol. 62 No. 2, 2015.
Stručni rad
BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS – OUR RESULTS
Ana Gudelj Gračanin
Ivan Marković
Jelena Lončarević
Majda Golob
Jadranka Morović-Vergles
Sažetak
Introduction. Patients with systemic lupus erythematosus
(SLE) are at an increased risk of developing low bone mass
(LBM) or osteoporosis, either because of the disease itself or
due to its treatment. Osteoporosis and osteoporotic fractures
signifi cantly contribute to morbidity and mortality. We
aimed to determine the associations of bone mineral density
(BMD) changes with the duration of SLE, age, gender, and
glucocorticoid treatment in SLE patients treated at our Department.
Patients and methods. BMD measurements of the lumbar
spine and total hip were performed by dual-energy Xray
absorptiometry (DXA). Osteoporosis and LBM were determined according to the 1994 World Health Organization
defi nition. In the statistical analysis, the independent
Mann-Whitney U test and Tukey post-hoc testing were
used.
Results. Th e study included 48 SLE patients (44 female
and 4 male), with a mean age of 45.8 years and an average
SLE duration of 9.8 years. Osteoporosis was diagnosed in
21 %, and LBM in 15 % of the patients. Th e mean ages of
the subgroups with normal BMD, LBM, and osteoporosis
were 41.1, 47.6, and 59.0 years, respectively. Variant analysis
showed a statistically signifi cant correlation between age
and BMD (p<0.05). Th e duration of SLE was signifi cantly horter in patients with normal BMD (7.3 years), compared
to patients with LBM (16.1 years) and osteoporosis (12.9
years) (p<0.05). Nearly all patients (47 of 48) were on longterm
treatment with glucocorticoids. One third (33.3 %) of
patients did not take vitamin D3, and 56.3 % did not take
calcium supplements.
Conclusion. Th e etiopathogenesis of decreased BMD in SLE
patients is multifactorial and includes both traditional and SLE-related risk factors. In our group of SLE patients age
and glucocorticoid treatment were the major risk factors for
LBM. Timely prevention and treatment of LBM and osteoporosis
in SLE patients, according to current knowledge, are
essential for reducing morbidity and mortality.
Ključne riječi
systemic lupus erythematosus; bone density; osteopenia; osteoporosis; glucocorticoids
Hrčak ID:
182721
URI
Datum izdavanja:
9.11.2015.
Posjeta: 1.327 *